PRNewswire

WARWICK, R.I., May 3, 2024 /PRNewswire/ -- The early outlook is in –this hurricane season could be one for the record books. A first forecast of the 2024 Atlantic hurricane season predicts at total of 23 storms, with 11 of those becoming hurricanes and five hurricanes could reach Category 3 status or stronger.   

The summer is primetime for hurricanes and tropical storms; it also happens to be the most popular time to travel.  So, the experts at InsureMyTrip, a... (continue reading...)

PANJIM, Goa, May 3, 2024 /PRNewswire/ -- As the global travel and tourism industry gears up for the prestigious Arabian Travel Market (ATM) Dubai 2024, there's one destination that's poised to make a significant impact – Goa, India. Renowned for its pristine beaches, rich cultural heritage, and vibrant communities, Goa is set to showcase its commitment to sustainable tourism at ATM Dubai 2024 with this year's theme: Innovation and Entrepreneurship: Transforming... (continue reading...)

USA News Group Commentary

Issued on behalf of Lithium South Development Corporation

VANCOUVER, BC, May 3, 2024 /PRNewswire/ -- USA News Group – Despite what appears to be a supply glut currently in the global lithium market, already there are signs of a lithium rebound on the horizon. According to Statista, global lithium demand is projected to grow through next year, while Fastmarkets predicts lithium supply will increase 30% in 2024. Fastmarkets also expects... (continue reading...)

A Revolutionary New Lens That Upgrades Prescription Glasses Offering Ultra-Responsiveness to Light, a Spectacular Color Palette and HD Vision at the Speed of Your Life

NEW YORK, May 3, 2024 /PRNewswire/ -- LensCrafters, part of EssilorLuxottica and one of the largest optical retail brands in North America, announced the launch of Transitions® GEN S™, including the fastest grey lens in the clear-to-dark photochromic category1. Ultra-responsive to light, the lenses... (continue reading...)

Study highlights opportunity for treatment intensification in this population since approximately 50% of patients with high-risk localized prostate cancer (HRLPC) experience disease recurrence within two years of surgery

SAN ANTONIO, May 3, 2024 /PRNewswire/ -- Johnson & Johnson announced today results from the open-label, single-arm Phase 2 Apa-RP study evaluating adjuvant treatment with ERLEADA® (apalutamide) and androgen deprivation therapy (ADT) in patients... (continue reading...)